Introduction to Bladder Cancer Immunotherapy Resistance

Immune checkpoint inhibitors targeting the PD-1 and PD-L1 pathways have fundamentally transformed management strategies for patients diagnosed with advanced or metastatic urothelial carcinoma. However, clinical response rates remain suboptimal, as most patients experience primary resistance or develop secondary disease progression. Unraveling the molecular drivers behind bladder cancer immunotherapy resistance is therefore a critical clinical priority in urological oncology. Emerging evidence highlights the pivotal role of the tumor microenvironment, where non-cancerous stromal and immune cell populations actively mediate therapeutic resistance. Among these microenvironmental mechanisms, macrophage-to-myofibroblast transition has emerged as a distinct cellular transdifferentiation pathway that remodels extracellular matrix architecture and dampens host immune responses. Although well-documented in tissue fibrosis, its specific contribution to bladder cancer progression and immune evasion was previously unknown. Multi-omics analyses now demonstrate that this transdifferentiation pathway establishes an immunosuppressive niche that physically restricts T-cell infiltration and impairs checkpoint inhibitor efficacy.

Elucidating Macrophage-to-Myofibroblast Transition in the Tumor Microenvironment

Macrophage-to-myofibroblast transition represents a plastic transdifferentiation process where tumor-associated macrophages undergo morphological and functional reprogramming into contractile myofibroblastic cells. During this phenotypic shift, myeloid cells downregulate classic phagocytic programs while increasing expression of alpha-smooth muscle actin and extracellular matrix proteins. Researchers performed comprehensive profiling combining bulk transcriptomics, single-cell RNA sequencing, and spatial transcriptomics across human bladder tumor samples to map this cellular state. Spatial transcriptomic analyses revealed distinct clusters of transitional cells localized at invasive tumor margins and fibrotic stromal areas. Through computational pseudotime trajectory mapping, investigators developed an 18-gene MMT signature that precisely quantifies this transdifferentiation program. High MMT signature scores strongly correlated with aggressive tumor stage, high histological grade, and reduced overall survival. Furthermore, evaluation of independent immunotherapy cohorts demonstrated that patients exhibiting elevated MMT signatures experienced severe resistance to checkpoint blockade, underscoring its clinical significance as a protective sanctuary for malignant cells.

The Pivotal Role of KLF6 in Transcriptional Reprogramming

Identifying upstream transcriptional drivers is essential for developing novel therapies targeting stromal plasticity. Through motif enrichment scanning, virtual gene knockouts, and spatial pseudotime modeling, Krüppel-like factor 6 was identified as the key transcription factor governing macrophage transdifferentiation. KLF6 directly binds to proximal promoter regions of key myofibroblast genes, most notably ACTA2, thereby driving structural lineage conversion. Functional in vitro experiments confirmed that KLF6 overexpression in myeloid cells induced robust expression of smooth muscle markers alongside cellular elongation. In vivo tumor models further showed that KLF6-driven transdifferentiation accelerated primary tumor growth and enhanced fibrotic stroma formation. Conversely, genetic knockdown of KLF6 effectively reversed the transdifferentiation phenotype, restoring normal macrophage functionality and reducing fibrotic matrix deposition. Molecular analyses confirmed that KLF6 serves as a central regulatory node connecting inflammatory signaling with downstream fibrotic transdifferentiation, presenting a compelling therapeutic target for reversing tumor microenvironment-mediated immune suppression.

Spatial Omics and PD-L1 Driven Immune Evasion

In addition to structural matrix remodeling, KLF6-driven macrophage transdifferentiation actively promotes local immune evasion through checkpoint ligand regulation. Spatial transcriptomics demonstrated that KLF6 expression strongly co-localizes with elevated PD-L1 expression on myeloid and stromal cells within bladder tumors. In vivo functional assays proved that KLF6 overexpression directly upregulates surface PD-L1, forming a potent immunosuppressive barrier that suppresses cytotoxic CD8+ T-cell activation and tumor infiltration. Consequently, effector lymphocytes become functionally exhausted and spatially excluded from malignant cell clusters, allowing unhindered tumor proliferation. Analysis of clinical trial cohorts confirmed that tumors enriched with KLF6-activated transdifferentiated cells consistently failed to respond to anti-PD-1 and anti-PD-L1 checkpoint inhibitors. By concurrently erecting a dense fibrotic physical barrier and upregulating inhibitory surface ligands, this axis coordinates a robust dual mechanism of immune evasion. Interrupting this path holds significant potential for re-sensitizing immunologically cold bladder tumors to standard immunotherapies.

Translational Screening for KLF6 Axis Drug Targets

To translate these fundamental biological findings into targeted clinical therapies, researchers conducted computational virtual drug screening and molecular docking studies. Utilizing the L1000CDS2 platform and CB-Dock2 molecular modeling algorithms, investigators evaluated thousands of candidate compounds for their ability to target the KLF6 signaling pathway. This computational approach successfully nominated small-molecule candidates capable of disrupting KLF6 transcriptional activity and inhibiting downstream transdifferentiation. In pre-clinical models, pharmacological inhibition of KLF6 successfully reversed the macrophage-to-myofibroblast phenotype, attenuated surface PD-L1 expression, and restored effective CD8+ T-cell infiltration into tumor cores. Importantly, combining KLF6 inhibitors with standard PD-1/PD-L1 checkpoint inhibitors demonstrated synergistic antitumor efficacy, resulting in substantial regression of established tumors in vivo. These findings provide a strong pre-clinical rational for developing novel combination therapies that pair KLF6-pathway inhibitors with existing immune checkpoint blockades to overcome resistance in advanced bladder cancer patients.

Future Clinical Perspectives for Urological Oncology

The discovery of KLF6 as a master regulator of macrophage transdifferentiation represents a major paradigm shift in understanding bladder cancer immune resistance. The 18-gene MMT signature provides a valuable predictive biomarker framework for identifying patients who are unlikely to benefit from anti-PD-1 or anti-PD-L1 monotherapy. Clinicians may soon utilize spatial transcriptomic profiling or biomarker panels to stratify patient risk prior to initiating expensive immunotherapeutic regimens. Furthermore, therapeutic strategies that target microenvironmental plasticity rather than focusing exclusively on epithelial tumor cells offer exciting new avenues for drug development. Combining KLF6-targeted agents with approved checkpoint inhibitors could successfully convert immunologically cold tumors into responsive microenvironments. As precision oncology continues to evolve, incorporating stromal and myeloid transcriptomic signatures into routine clinical workflows will empower oncologists to design tailored combination treatments. Ultimately, inhibiting KLF6-driven immune evasion has immense potential to improve therapeutic response rates and extend survival outcomes.

Frequently Asked Questions

What is macrophage-to-myofibroblast transition in bladder cancer?

Macrophage-to-myofibroblast transition is a cellular transdifferentiation process where tumor-associated macrophages undergo functional lineage remodeling to become myofibroblast-like cells. These converted cells express smooth muscle markers like alpha-smooth muscle actin and generate dense extracellular matrix components. In bladder cancer, this phenotypic conversion establishes a fibrotic tumor microenvironment that physically restricts immune cell infiltration and actively promotes PD-L1-mediated immune evasion, leading to therapeutic resistance against immune checkpoint inhibitors.

How does KLF6 contribute to immune evasion and drug resistance?

Krüppel-like factor 6 functions as a master transcription factor that directly binds to the ACTA2 promoter, driving the transdifferentiation of macrophages into myofibroblasts. This regulatory process upregulates surface PD-L1 expression on immune and stromal cells, creating a potent immunosuppressive shield. Consequently, functional CD8+ cytotoxic T cells are excluded and inactivated, preventing effective immune destruction of malignant cells and driving clinical resistance to standard PD-1 and PD-L1 checkpoint blockades.

What are the clinical implications of targeting the KLF6 axis?

Targeting KLF6 or its downstream effectors offers a promising therapeutic strategy to dismantle the fibrotic immunosuppressive barrier in advanced bladder cancer. Virtual drug screening has identified candidate small molecules that inhibit KLF6 activity, successfully suppressing macrophage transdifferentiation and reducing PD-L1 expression in pre-clinical models. When combined with immune checkpoint inhibitors, targeting this axis restores T-cell infiltration, reverses therapeutic resistance, and significantly enhances antitumor treatment efficacy in non-responsive patient populations.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult qualified healthcare professionals regarding medical conditions. Refer to the latest local and national guidelines for clinical practice.

References

1. Chen Y et al. KLF6-driven macrophage-to-myofibroblast transition promotes PD-L1-mediated immune evasion in bladder cancer. Int Immunopharmacol. 2026 Aug 10. doi: undefined. PMID: 42574804.


2. Balar AV et al. Atezolizumab as first-line therapy in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017;389(10064):67-76.


3. Tang X et al. Macrophage-to-myofibroblast transition in fibrosis and cancer microenvironments. Front Immunol. 2022;13:925480.